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Comparative Efficacy of Amoxicillin-Clavulanate, Cloxacillin, and Vancomycin Against
Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus Endocarditis in Rats
Since the introduction of methicillin into clinical medicine
in 1959 the prevalence of Staphylococcus aureus strains
resistant to this antibiotic has reached epidemic propor-
tions in certain geographic areas. The therapeutic options
for treating such strains are largely limited to vancomy-
cin. The ll-lactamase-resistant penicillins and cephalospo-
rins have been controversial for the treatment of infections
caused by these organisms [1].
Beta-lactamase inhibitors (e.g., clavulanic acid and sul-
bactam) have a weak intrinsic antibacterial activity but act
synergistically with ll-lactamase-labile antibiotics against
most ll-lactamase-producingorganisms such as methicillin-
sensitive S. aureus (MSSA). In the case of methicillin-
resistant S. aureus (MRSA), the resistance mechanisms are
more complex and lesswellunderstood [1]. However,when
the ll-lactamases of MRSA strains are inhibited by the ad-
dition of clavulanic acid, the minimal inhibitory concen-
trations (MICs) of amoxicillin and penicillin against these
organisms are reduced by 2-4 dilutions to values of 4-16
ug/ml, for most of the strains tested [2-4]. While many
authors consider this increase in in vitro activity to be of
questionable significance, Washburn and Durack [5]
showed with a rabbit model of S. aureus endocarditis that
the combination of ampicillin and sulbactam was highly
effective against endocarditis caused by two different
nafcillin-resistant S. aureus strains and that the combina-
tion was superior to nafcillin alone. Because these in vitro
and in vivo observations deserve further scrutiny, we de-
signed this study: (1) to determine the MICs of amoxicil-
lin and oxacillin, alone or in combination with clavulanic
acid, for a largenumber of recent clinical isolates of MSSA
and MRSA; and (2) to study the in vivo efficacy of the
combination of amoxicillin with clavulanic acid against
MSSA and MRSA strains in a rat model of S. aureus en-
docarditis and to compare it to that of cloxacillin and van-
comycin.
Materials and Methods
In vitro study. (1) Microorganisms. A total of 167
strains of S. aureus originating in different locales (Eu-
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rope, the USA, Australia) were studied. All of the strains
were ll-lactamase producers and thus wereresistant to pen-
icillin. When tested by a disk diffusion method as recom-
mended by the National Committee for Clinical Labora-
tory Standards (NCCLS) [6], 71 strains were found to be
methicillin-sensitive (Kirby Bauer inhibition diameter ~13
mm using a l-ug oxacillin disk in Mueller Hinton agar
[MH; Difco Laboratories, Detroit] without NaCl). Ninety-
six strains were methicillin-resistant (Kirby Bauer inhibi-
tion diameter "10 mm under the same testing conditions).
(2) Antibiotics. Standard antimicrobial reference
preparations of vancomycin(Eli Lilly, Indianapolis), amox-
icillin, oxacillin,amoxicillin-clavulanate (Augmentin), and
clavulanic acid (Beecham Research Laboratories, Brock-
ham Park, UK) were used.
(3) Susceptibility testing. MICs weredetermined by the
microbroth dilution method [7]with an automatic device
(MIC 2000 Dynatech, FRO). MICs of oxacillin, amoxicil-
lin, and oxacillin in combination with clavulanic acid
(added at a fixed concentration of 4 ug/ml.), and
amoxicillin-clavulanic acid (in a ratio of 2:1), were per-
formed in cation-supplemented MHB (50 mg/L of Ca"
and 25 mg/L of Mg") with 20/0 NaCl. For vancomycin
MIC determinations, cation supplementation was not
used. Final inocula of 5 x lOS to 5 X 106 cfu/mL were
prepared from an overnight culture in MH. MICs were
determined by visual inspection after 24 h of incubation
at 35°C. For a selection of strains, MBC were determined
by macrobroth dilution method [8] and defined as the
lowestconcentration of antibiotic that killed 99.9% of the
initial inoculum after 24 h of incubation.
In vivo study. (1) Microorganisms. Four different
strains of S. aureus were studied in the rat model: two
MSSA (MSSA-l, MSSA-2) and two MRSA (MRSA-l,
MRSA-2).
(2) Production ofendocarditis. Sterilevegetationswere
produced in female Wistar rats (180-200 g) by modifica-
tion of a method already described [9]. Briefly, a polyeth-
ylene catheter (PP 10, Portex, Hythe, Kent, UK) was in-
serted across the aortic valve through the right carotid
artery and secured with a silk ligature. Rats were injected
in the tail vein with 0.5 mL of saline containing 105 cfu
of S. aureus (MSSA-I, MSSA-2, MRSA-I, or MRSA-2)ei-
ther 4 d (half of the experiments) or 12 h after catheter-
ization. Both experimental designs produced bacterial
counts of 106_107 cfu/g of vegetations 12 h after iv bac-
terial challenge. Since the effect of treatment was found
to be similar after both experimental designs (bacterial
challenge 4 d and 12 h after catheterization), the results
were pooled.
(3) Evaluation ofinfection. Todetermine the incidence
and the magnitude of valvular infection, control rats cho-
990
sen at random were sacrificed 12 h after iv injection of
bacteria (i.e., at the time treatment was started in the test
rats). Treated rats were killed after 3 d of therapy, 12 h
after the last antibiotic injection, when no antibiotic ac-
tivity was detectable in blood. Aortic vegetations wereex-
cised, weighed, homogenized in 1 mL of saline, and seri-
ally diluted and plated. Colonies were counted after 24 h
of incubation at 37°C, and the results expressed in 10g10
cfu/g of vegetation. This method permitted the detection
of lQ2 cfu/g of organ. Bacteria recovered from the vegeta-
tions of treated rats were routinely stored at - 20°C for
subsequent MIC determinations.
(4) Treatment regimens. Antibiotics were started 12h
after infection and weregivenfor 3 d. 'Ireatment wasstarted
early to minimize mortality from overwhelming infection.
Cloxacillin (Orbenin injectable, 1 g, Beecham Research
Laboratories) was given sc at 200 mg/kg every 5 h. The
adult formulation of parenteral Augmentin (Augmentin
injectable, 1.2g, containing amoxicillinand clavulanicacid
in a ratio of 5:1, Beecham) was given sc at 150mg/kg of
amoxicillin and 30 mg/kg of clavulanic acid every 5 h.
1\vo different regimens of vancomycin (Vancocin injecta-
ble 500 mg, Eli Lilly) were tested: 30 mg/kg every 12 h
or 30 mg/kg every 6 h sc.
(5) Antibioticserumlevels. Serum samples weretaken
from normal rats at various intervals after one sc injec-
tion and levels of cloxacillin and of vancomycin were de-
termined by microbiologic assay using a test strain of
Bacillus subtilis (Subtilis spore suspension, Difco Lab-
oratories). The serum values of amoxicillin and clavulanic
acid were measured by Beecham Research Laboratories
using a microbiologic assay.
(6) Statistical evaluation. Nonparametric analysis with
the Wilcoxon Mann-Whitney test was used to compare the
bacterial counts in the vegetations.
Results
In vitro study. (1) MSSA strains. Figure 1 (upper
panels) illustrates results. Of the MSSA strains, 62 (87%)
of71 wereresistant to amoxicillin according to the criteria
of the NCCLS (MIC ~ 0.5 ug/ml.) [7]: MIC so 8 ug/ml.;
MIC go 128 ug/ml.; range ~ 0.12-256 ug/ml., The addi-
tion of clavulanic acid reduced the MIC so for amoxicillin
to 1 ug/rnl., the MICgo to 2 ug/ml., and the range to
~O.l2-4l1g/mL, making thestrains susceptibleto Augmen-
tin (MIC ~ 4/2 ug/ml.). All strains were susceptible to
oxacillin (MICso 0.25 I1g/mL, MIC go 0.5 I1g/mL, range
~O.l25-1.0 ug/ml.), and their MICs wereonly slightly in-
fluenced by the addition of clavulanic acid (MIC so ~.012
ug/ml.; MIC90 0.25 ug/ml.; range ~O.l2-o.5l1g/mL). All
MSSA strains werealso susceptible to vancomycin (MICso
1 ug/ml.; MICgo 1 j.Lg/mL; range 1-2 ug/ml.).
(2) MRSA strains. The lower panels of figure 1 illus-
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trate the results. The addition of clavulanic acid reduced
the amoxicillinMICso from 32to 8I1g/mL, the MIC90 from
128to 16I1g/mL, and the range from 8-128to 2-32 ug/ml.,
but most of these organisms remained resistant to Aug-
mentin according to the criteria of the NCCLS (MIC ~
8/4 ug/ml.). In contrast, the addition of clavulanic acid
to oxacillin did not influence the MIC (oxacillin MICso
in the presence of clavulanic acid 32 ug/rnl., MIC go 128
I1g/mL,range 2-256I1g/mL); most strains remained highly
resistant. All of the MRSA strains weresusceptible to van-
comycin (MICso, l ug/ml.: MIC go 2 ug/rnl.; range 0.25-2
I1g/mL).
In vivostudy. (1) Susceptibility ofchallengedstrains.
The MICs and minimal bactericidal concentrations
(ug/ml.) of the three different antibiotics for the four
strains used in vivo were as follows: MSSA-1- oxacillin
0.25/64, Augmentin 1.0/16, vancomycin 1.0/4.0; MSSA-
2-oxacillin 2.0/64, Augmentin 1.0/32, vancomycin
1.0/4.0; MRSA-l-oxacillin 64/512, Augmentin 16/64,
vancomycin 1.0/8.0; MRSA-2-oxacillin 64/512, Augmen-
tin 16/64, vancomycin 0.25/8.0.
(2) Antibioticserumlevels. After a dose of 150mg/kg
of amoxicillin-clavulanatesc the peak serum levelof amox-
icillin reached 93 ± 31I1g/mL, dropping to no detectable
levels after 4 h. The peak serum level of clavulanic acid
was 21 ± 7 I1g/mL and after 2 h no clavulanic acid was
detectable. After one injection of cloxacillin 200 mg/kg
sc, the peak serum level exceeded 200 ug/rnl., but no an-
tibiotic was found in serum 4 h later. One injection of van-
comycin30 mg/kg sc resulted in a peak of 36 ug/ml., how-
ever, levelswereundetectable 6 h later. Thus, at the dosage
used in rats, the antibiotics used in these experiments
reached peak levelscomparable to those in humans after
conventional therapeutic doses.
Comparative efficacyoftreatment for 3 d. (1) MSSA
strains. Cloxacillin given at 200 mg/kg every 5 h, and
amoxicillin/clavulanate givenat 150mg/kg every 5 h were
both highly and equally effective (P < 10-10compared to
controls), sterilizing more than 90% of the infected vege-
tations (figure 2, upper part). The vancomycin 30 mg/kg
regimen giventwice a day (figure 2) was effective in reduc-
ing valvular infection (P < 10-2 compared to controls), but
remained less active than cloxacillin and amoxicillin-
clavulanate. When the vancomycin dosage was increased
to 30 mg/kg every 6 h (figure 2, upper right), the efficacy
of the three different antibiotics became similar.
(2) MRSA strains. As expected, the cloxacillin regi-
men clearly failed to cure infection and all of the rats re-
mained highly infected after 3 d of treatment (figure 2,
lower panels). In contrast, amoxicillin-clavulanate showed
a definite efficacy against both MRSA strains (P < lO-s
with MRSA-l and P < 10-3 with MRSA-2, when com-
pared to controls) and sterilized>90% of the infectedvege-
tations.
With regard to vancomycin, the twice-a-day regimen
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Figure 1. In vitroMICdetermination(microbroth dilution)expressed as a percentage of strainsinhibited at different
antibioticconcentrations. Upper, Methicillin-susceptible strains(MSSA). Lower, Methicillin-resistant strains(MRSA).
Amoxicillin-clavulanate was given in a ratio of 2:1.
used against the MRSA-I strain failed to producea sig-
nificanteffecton the valvular counts whencompared to
controls (P = .6); increasing the doses to four times a
day only marginally improved the outcomeof infection
(P = .1when compared to controls). Against theMRSA-2
strain, vancomycin given four timesa day improved out-
comewhencompared to controls (P = .01) and to clox-
acillin (P = .01), but was clearly less effective than
amoxicillin-clavulanate (P = .02)(figure 2, lower right).
MICsof bacteriarecovered fromrats that remained in-
fected at the end of the various treatments were equal to
those of the organisms used for the bacterial challenge.
Discussion
Thisstudyof the treatmentof methicillin-resistant S. au-
reus endocarditis in rats revealed three interesting obser-
vations. (1) Clavulanic acid markedly reduced the
amoxicillin-resistance of the MRSA strains in vitro, but
had littleeffecton the oxacillin-resistance of thoseorgan-
isms. (2)Thecombination of amoxicillin-clavulanate (Aug-
mentin) wasvery effective in vivo not onlyagainstMSSA
but also, andmoreimportantly, against MRSA strains that
were marginally susceptible to this combinationin vitro
according to current MIC interpretive standards [7]. (3)
Yancomycin was less active in vivo than amoxicillin-
clavulanate against MRSA strains, whereas it was uni-
formly active against these organisms in vitro.
With regard to the in vitro results, most of the MRSA
strains are also a-Iactamase producers so that penicillin
derivatives otherthan penicillinase-resistant penicillins are
rarely if ever tested against them. When clavulanic acid
isassociated witha-Iactam antibiotics to neutralize theef-
fect of a-Iactamases, an enhanced in vitro effect of the
penicillinase sensitive penicillins whencompared to that
of the penicillinase resistant penicillins alone can be ob-
served on MRSA strains. This phenomenon has already
beenobserved both with amoxicillin-clavulanate combi-
nation [2-4]and withan ampicillin-sulbactam combina-
tion [10, 11], and mightrelateto the observation that pen-
icillin and amoxicillin display a greater in vitro activity
on penicillin-sensitive S. aureus strains than do such
penicillinase-resistant penicillins as oxacillin or methicil-
lin. This difference in intrinsicactivity may be ascribed
to differences in the targetmolecules to which the respec-
tivea-Iactam antibiotics attach, e.g., differences in target
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Figure 2. Treatment for 3 d with various antibiotic regimens begun 12h after bacterial challenge. Each point represents
the number of organisms recovered in aortic valve vegetations (veg) 12 h after completion of therapy. For controls,
values are those found in rats killed at beginning of treatment. Numbers at the bottom of each column are the number
of rats in each category of treatment: vanco = vancomycin, cloxa = cloxacillin, aug = Augmentin (amoxicillin plus
clavulanate). MSSA = methicillin-susceptible strains, MRSA = methicillin-resistant strains.
penicillin binding proteins [4]. Such differences may ex-
plain why the addition of clavulanic acid to oxacillin had
no beneficial effect on the MICs of MRSA strains while
it improved the MIC of amoxicillin.
With regard to the marked in vivo efficacy of amox-
icillin-clavulanate against MRSA strains, Washburn and
Durack [5] obtained similar results with a combination
of ampicillin and sulbactam in a rabbit model of en-
docarditis infected with a nafcillin-resistant S. aureus. As
in our study, according to the MIC interpretive standards,
the strains studied by Washburn and Durack were only
marginally sensitive in vitro to the combination of am-
picillinand p-lactamase inhibitor. The MIC for sulbaetam-
ampicillin was 25 ug/ml, in the Washburn-Durack experi-
ments, while the amoxicillin-clavulanate MIC was 16
ug/rnl, for both MRSA strains in-our experiments. Thus,
both studies suggest that despite moderate in vitro sensi-
tivities, the combination of ampicillin (respectiveof amox-
icillin) with a p-lactamase inhibitor might exhibit excel-
lent effectiveness in vivo. The doses used in both animal
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models of endocarditis (rabbit and rat) were chosen so
as to give serum levels similar to those achieved in humans
receiving full parenteral therapy.
With respect to the in vitro interpretive standard for sen-
sitivity or resistance of staphylococci to amoxicillin-
clavulanate (resistant category, MIC ~ 8 I1g/mL), most
of the MRSA strains were resistant in our study, having
an MIC of 8 or 16I1g/mL. If one considers, however, the
similar break-point value proposed for organisms other
than staphylococci, most of the strains would be consid-
ered to be susceptible (MIC ~ 8 I1g/mL) or moderately
susceptible (MIC = 16I1g/mL) to the combination. Like-
wise, the usual MIC values of the MSSA strains for
amoxicillin-clavulanate are near the upper limit of sus-
ceptibility (~4I1g/mL), if one considers the category MIC
break points for staphylococci only. Given the success of
treatment with a combination of ampicillin (amoxicillin)
plus clavulanic acid achieved in experimental endocardi-
tis due to several MRSA strains, perhaps it would be worth-
while to reconsider the interpretive break points for MICs
currently recommended for Augmentin against staph-
ylococci [6].
With regard to the efficacy of vancomycin against the
MRSA strains, while it showed an excellent in vitro activ-
ity, its in vivo efficacy was inferior to that of amoxicillin-
clavulanate after 3 d of treatment. While unpublished ex-
periments have shown that this difference disappeared after
6 d of treatment, amoxicillin-clavulanate sterilized the vege-
tations faster than did vancomycin.
Thus, the association of amoxicillin and clavulanic acid
(Augmentin) was shown to be effective in the treatment
of experimental endocarditis due to both MSSA and
MRSA strains. They proved particularly superior to the
efficacy of vancomycin against the MRSA strains. If this
observation is confirmed in other infections due to MRSA
strains, amoxicillin-clavulanate could be considered for
clinical trials in the treatment of infections caused by
MRSA strains.
L. CANlONI, A. WENGER, M. P. GLAUSER, J. BILLE
Department of Internal Medicine, Division of
Infectious Diseases, Centre Hospita/ier Universitaire
Vaudois, Lausanne, Switzer/and
993
References
1. Chambers HF. Methicillin-resistant staphylococci. Clin
Microbiol Rev 1988;1:173-186
2. Graninger N, Leitha T, Georgopoulos A, Witte W, Griffin
K. Antimicrobial activity of penicillins plus clavulanic acid
against Staphylococcus aureus [abstract). In: Proceedings
of the 7th International Symposium on Future Trends in
Chemotherapy, 1986
3. Hofstra SY,Van de Sande F, Mouton RP. The effect of clavu-
lanic acid on the activity of penicillins on methicillin resis-
tant S. epidermidis and S. aureus. Proceedings of the 13th
ICC, Vienna, 1983:55/12-55/15
4. McDougal LK, Thornsberry C. The role of l3-lactamase in
staphylococcal resistance to penicillinase-resistant penicil-
lins and cephalosporins. J Clin MicrobioI1986;23:832-839
5. Washburn RG, Durack or.Efficacy of ampicillin plus a 13-
lactamase inhibitor (CP-45,899)in experimental endocardi-
tis due to Staphylococcus aureus. J Infect Dis 1981;144:
237-243
6. National Committee for Clinical Laboratory Standards. (Ap-
proved standard M2-A3 and supplement MlOO-S, M2-A3-
SI, table 2). Performance standards for antimicrobial disk
susceptibility tests. Villanova, Pa: National Committee for
Clinical Laboratory Standards, 1984
7. National Committee for Clinical Laboratory Standards. Ten-
tative standard: M7-Tand Mllo-S M7-A, SI, table 7. Stan-
dard methods for dilution antimicrobial susceptibility tests
for bacteria which grow aerobically. Villanova, Pa: Na-
tional Committee for Clinical Laboratory Standards, 1982
8. Schoenknecht FD, Sabath LD, Thornsberry C. Susceptibility
tests: special tests. In: Lennette EH, Balows A, Hausler
WJ Jr, Shadomy HJ, eds. Manual of clinical microbiol-
ogy. Washington, DC: American Society for Microbiol-
ogy,1985
9. Heraief E, Glauser MP, Freedmann LR. Vancomycin pro-
phylaxis of streptococcal endocarditis in rats. In: Nelson
JD, Grassi C, eds. Current chemotherapy and infectious
disease. Vol 2. Washington DC: American Society for
Microbiology, 1980:911-913
10. Retsema JA, English AR, Girard AE, Anderson M, Bren-
nan L, Cimochowski C, Faiella J, Herbert C. Sulbactam
and ampicillin: synergisticantibacterial activity against hos-
pital isolates of enterobacteriaceae, methicillin-resistant
staphylococcus, and anaerobes. In: Proceedings of the 13th
ICC, Vienna, 1983(59):59/1
11. Kazmierczak A, Duez JM, Pechinot A, Nordmann P, Labia
R. In vitro bactericidal activity of suJbactam plus ampicillin
against methicillin-resistant Staphylococcus aureus. Rev
Infect Dis 1986;8(S5):S549-S554
